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ABSTRACT 
Context 
The introduction of combined antiretroviral treatment (cART) reduced HIV related mortality 
more than 70% and the rate of new infection in children continue to decrease considerably.  
However this benefit is threatened by the emergence of drug resistant strains of HIV. Studies 
exploring the patterns of drug resistance in the paediatric population are crucial for policy 
makers and for individual patients’ management. In sub-Saharan Africa where HIV-1 subtype 
C is more prevalent, there is a limited number of paediatric studies exploring the drug 
resistance patterns. To get more insight on this problem, we explored the drug resistance 
mutations (DRMs) patterns in a paediatric population attending a referral public paediatric 
HIV clinic. 
Methodology 
The study was a cross-sectional retrospective descriptive study. Convenience sampling 
method was used and all paediatric patients (0-14 years) who underwent genotypic HIV drug 
resistance testing at Empilweni Clinic between January 1st, 2004 and February 28th, 2012 
were included. Demographic and clinical data were collected from the clinical electronic 
database and DRM frequencies related to treatment exposure were presented.  
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Results 
During our study period, 63 patient samples were sent for HIV genotyping drug resistance 
testing. Eleven samples did not meet the inclusion criteria. Among the 52 patient samples 
retained, 44 patients (84.6%) had a successful HIV amplification and all were infected with 
HIV-1 subtype C. Ninety one percent (n=40) of the patients had at least one DRM isolated 
but in only 78% (n=34) did these mutations translate into genotypic drug resistance to at least 
one antiretroviral drug (ARV) used in South Africa. Nucleotide reverse transcriptase 
inhibitors (NRTI) mutations were the most commonly identified with M184V being the most 
prevalent (64.4%; n=29). This was associated with thymidine analogue mutations (TAMs) in 
36.3% of the patients (n=16). TAMs were identified in 25% (n=11) of the patients. K65R and 
Q151M were rarely identified in our cohort. V106M and K103N were the most common non-
nucleotide reverse transcriptase inhibitors (NNRTI) mutations and were both identified in 
21.9% (n=7) of the patients exposed to NNRTI-based regimen. V82A was the most 
commonly identified protease gene (PR) mutation in 29.3% (n=12) of the cases.  
Forty eight percent of the patients (n=21) had a dual class resistance and 11.4% (n=5) had 
resistance to ARVs from all the three classes. Over a quarter (27.2%, n=12) of the patients in 
our cohort were still sensitive to all ARVs used in South Africa. The development of drug 
resistance was not associated with any clinical characteristic in our cohort.   
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Conclusion 
The drug resistance mutations identified in paediatric patients failing cART show a complex 
pattern with some failing patients still sensitive to all ARVs while others harbour complex 
resistance mutations. Therefore, regular counselling to optimize adherence and regular viral 
load monitoring for early detection of failure may be important tools for continued cART 
success. Given the complexity of the DRMs patterns in paediatric patients, the HIV drug 
resistance test is warranted to guide the choice of appropriate cART regimens.  
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CHAPTER 1.  INTRODUCTION 
1.1. Background  
 
Human immunodeficiency virus (HIV) infection is a major public health concern worldwide. It 
is one of the leading causes of child mortality in the world. In 2010, 4.0% of the total number 
of child deaths in Africa were due to HIV infection, a rate four times higher compared to 
Europe and North America (1).  South Africa has the highest HIV burden in the world, with an 
estimated 14.0% of all infected children living with HIV in the world residing there (2).  
Furthermore, in 2010, it was estimated that  HIV contributed around 40.0% of mortality among 
South African children aged between 1-59 months (2, 3).  
 
Large-scale efforts have been made to stop this epidemic and it has been placed among the top 
world health priorities with target to virtually stop the epidemic spread by 2015. Nevertheless, 
South Africa still experience many new cases of HIV infection in children (4). One of the most 
successful interventions towards this goal was the initiation of antiretroviral drugs (ARVs) for 
prevention and treatment of HIV. The combinations of three ARVs, often referred to as 
combined antiretroviral therapy (cART), has drastically altered Acquired Immune Deficiency 
Syndrome (AIDS)  from an almost uniformly fatal disease to a chronic manageable one (5). 
 
To date, there are over 20 ARVs available to treat HIV infection. They fall into six categories 
inhibiting different viral enzymes and different steps in the viral lifecycle (6, 7).  
Table 1 summarizes the main classes of ARVs, their mechanisms of action and the most 
commonly selected mutations associated with HIV drug resistance.  
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In South Africa, the Comprehensive Plan for the Care, Management and Treatment (CCMT) of 
HIV and AIDS, was initiated in April 2004 with the objective to progressively achieve 
universal antiretroviral treatment access (8). 
 
 As cART was initiated, it dramatically modified the course of HIV infection in children, 
reducing mortality five-fold or more and resulting in high survival rates into adulthood (9). 
cART have been shown to reduce HIV related mortality by more than 70% both in developed 
countries and in resource-limited settings (10, 11). Without treatment one third of HIV-infected 
children die in their first year of life and 50.0% before their second birthday (12). Furthermore, 
cART delays the emergence of drug resistant HIV strains, which accumulated rapidly in the 
pre-cART era when monotherapy was still in use, but challenges remain (13). 
 
The roll-out of cART in resource-limited countries has been identified as a global public health 
priority. With the collaboration of various international organizations, governments of 
developing countries managed to scale-up cART access but have not yet reached universal 
access as the treatment coverage for children is only 34.0% (95% CI: 31-39%) (14).  
 
However, increasing cART coverage in resource-limited settings also brings with it the risk of 
emerging HIV drug resistance potentially compromising future treatment options (15). 
Amongst the paediatric population with access to cART, the resistant virus can be acquired 
from inadequate adherence or from use of Prevention of Mother-to-Child Transmission 
(PMTCT) regimens (acquired HIV drug resistance) (16) or transmitted to newly infected 
individuals (transmitted HIV drug resistance) when a patient is infected by an HIV-1 strain 
already resistant to ARVs (17, 18).  One of the consequences of cART scale-up is treatment 
failure that selects for drug resistant HIV-1 (15). This is more common in the paediatric 
population due to various adherence challenges (19, 20).  
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Table 1: Major classes of ARVs and commonly selected mutations (6, 7, 21). 
Drug class Mode of action Example Common mutations 
selected by the drug 
Generic name Abbre-
viation  
 
 
Nucleoside 
reverse 
transcriptase 
inhibitor 
(NRTI) 
 
 
Deoxyribonucleic 
acid (DNA) chain 
terminators and 
inhibit reverse 
transcription 
 
Abacavir  ABC K65R, L74V 
Didanosine  ddI K65R, L74V 
Emtricitabine  FTC M184V 
Lamivudine  3TC M184V 
 
Stavudine  
 
d4T 
TAMs (41L, 67N, 70R, 
210W, 215Y/F, 
219Q/E), K65R 
Tenofovir  TDF K65R, K70E 
Zidovudine  AZT TAMs (41L, 67N, 70R, 
210W, 215Y/F, 219Q/E) 
 
Non-
nucleoside 
reverse 
transcriptase 
inhibitors 
(NNRTI) 
 
Bind to the 
hydrophobic pocket 
inhibiting the 
reverse transcriptase 
enzyme  
Efavirenz  EFV K103N , V106M 
Etravirine  ETR L100I, K101E/P, Y181C 
Nevirapine  NVP Y181C , K103N, 
V106M 
Rilpivirine  RPV K101E/P, E138K, 
Y181C, Y188L, M230L 
 
Protease 
inhibitors  
(PI) 
 
Target the viral 
enzyme required for 
cleavage of viral 
precursors and final 
assembly of viral 
particles 
Atazanavir/ 
Ritonavir  
ATZ/r I50L, I84V, N88S 
Darunavir/ 
Ritonavir  
DRV/r I47V, I50V, I54M, 
L76V, I84V 
Lopinavir/ 
Ritonavir 
LPV/r V32I, I47V, L76V, 
V82A/F/T/S 
Indinavir/ 
Ritonavir 
IDV/r M46I, V82A/F/T/S, 
I84V 
Nelfinavir/
Ritonavir  
NFV/r D30N, L90M 
Integrase 
inhibitor (IN) 
Inhibit the 
attachment of pro-
viral DNA to host-
cell genome 
 
Raltegravir  
 
RAL 
 
G140S, Q148H,  N155H 
Fusion/Entry 
inhibitor 
(FI)* 
Block the fusion of 
the viral particle to 
their target cells 
 
Enfuvirtide  
 
T-20 
 
G36S/V, 38M, Q40H 
Co-receptor 
inhibitors 
(CRI) 
Interfere with the 
entry of HIV in the 
target cell 
Aplaviroc  APL R305K, Q315R, T319K, 
P363S, A373T, N413T, 
S437P, and T467I. Maraviroc  MVC 
  *Not yet registered in South Africa (22). 
  
 
4 
In developed countries, the rate of cART failure in children and adolescents is estimated to be 
twice that observed in adults, with risk increasing with duration of therapy and with entry into 
adolescence (23).  
 
In developing countries it has been shown that the prevalence of transmitted drug resistance 
has increased progressively since the roll-out of cART (24). The overall prevalence of drug 
resistance was estimated to increase at 29.0% per year in east Africa where the cART roll out 
programme started earlier and 14.0% per year in southern Africa. This increase in prevalence 
was directly linked to cART coverage (14, 15).  
 
Furthermore, it has been shown that children, highly vulnerable to HIV infection, are at higher 
risk of developing drug resistance and the rate is higher compared to adults (25).  This is a 
major concern as this population is expected to be on lifelong cART from early infancy.  
Currently, in resource-limited settings, there are few treatment options while in developed 
countries it is possible to tailor cART regimens more individually and prescribe fully active 
cART even for multi-resistant HIV (26, 27).  
 
In developed countries the prevalence of HIV drug resistance seems to be stabilizing over time 
mainly due to continuous and timely VL monitoring added to individualized cART from pre-
treatment HIV drug resistance testing (28). Pre-treatment HIV drug resistance testing is not 
feasible in resource-limited settings at present due to the high cost. As expected, in developing 
countries, cases of drug resistance are more likely to increase progressively as the cART 
coverage and the duration on cART increases (15, 24).  
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HIV drug resistance has been extensively explored in adult populations in developed countries. 
However, data on paediatric HIV drug resistance is still scarce, especially in resource-limited  
settings like sub-Saharan Africa even though it is home to more than 90.0% of children living 
with HIV (14, 29). More studies from developing countries are needed to elucidate the 
problem.  
 
 
1.2. Literature review 
1.2.1. Development of HIV drug resistance   
 
Due to the constantly changing HIV genome, the virus has the ability to change its genetic code, 
accumulating mutations which may confer a decreased susceptibility to the ARVs. However, all 
the mutations do not results in viable viruses. Some mutations arising in HIV genome are lethal 
to the virus itself and others are only polymorphisms which don’t cause resistance to ARVs by 
themselves but may act in concert with other mutations to enhance resistance (30). 
 HIV is said to have developed ‘drug resistance’ as it progressively evades the effects of these 
medication on its replication abilities compared to wild type HIV. Drug resistance is a continuum 
and it varies from low level to high level drug resistance (30) 
The development of drug resistance may be due to different factors, these include viral, drug and 
host related factors.  
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1.2.2. Factors contributing to HIV drug resistance 
1.2.2.1. HIV biology 
 
HIV has been classified into two types: HIV-1 and HIV-2. HIV-1, which is the most common 
pathogenic strain, is divided into group M (major) and three minor groups N (non-M, Non-O), 
O (Outlier) and P (Pending identification of further human cases) which was recently discovered. 
Group P has so far been isolated from only one Cameroonian woman (31, 32). Due to substantial 
natural genetic variation,  HIV-1 group M have been further sub-classified into nine subtypes (A 
through D, F through H,J and K) and numerous circulating recombinant forms (CRFs) (32).  
 
Although subtype B is most prevalent in North America and Europe, non-B subtypes 
predominate elsewhere with subtype C infection dominant in Southern Africa (32). Various 
studies have shown that cART benefits patients irrespective of the viral subtype, but subtypes C 
and D may be more virulent (33, 34). 
 
Different HIV subtypes are prone to encode different amino acids substitution due to differences 
in codon sequences at positions associated with drug-resistance mutations. This difference might 
affect not only the rate of emergence of resistance mutations but also the cross-resistance to 
ARV’s within the same class, potentially affecting antiviral responsiveness and clinical 
outcomes (35, 36).  For example, group O HIV-1 and HIV-2 viruses manifest high-level innate 
resistance to some NNRTIs as a result of mutations in the reverse transcriptase gene that are 
present as natural polymorphisms (37-39).  
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Furthermore, even though resistance mutations are comparable in different viral subtypes, it has 
been shown that different subtypes develop certain drug resistance mutations more readily than 
others and this might be through different mutation pathways.  HIV-1 subtype C, which is more 
common in sub-Saharan Africa, is more prone to develop V106M and K65R mutations compared 
to subtype B common in Europe and North America (40, 41).  
In addition, HIV has a short half-life. In order to keep the balance with its clearance it has a 
very high replication rate which is error prone as a result of the poor proof-reading capability 
of the HIV-1 reverse transcriptase enzyme during replication. This results in the introduction of 
either polymorphisms or mutations potentially reducing the efficacy of ARVs. The mutation 
rate averages 3 × 105 mutations/base/replication cycle (30, 42, 43).  
 
This implies that circulating viruses are not represented by a unique virus genotype, but by 
numerous different genetically related viral variants referred to as “quasispecies” as initially 
designated by Eigen in 1993 (44). Quasispecies in a patient diversify progressively over time 
(45) which results in a progressive expansion of the complexity of HIV resistant variants in 
untreated patients (46). The mutation that develops can be either specific to one ARV or lead to 
reduced susceptibility to a number of ARVs (cross resistance) or increased susceptibility to 
certain ARVs (27). For example, the presence of K65R mutation confers resistance to TDF, as 
well as cross-resistance to ABC and ddI (Table 1). By contrast, the presence of M184V which 
causes resistance to 3TC (Table 1), enhances susceptibility to AZT, d4T and TDF (21). 
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1.2.2.2. Genetic barrier and HIV drug resistance  
 
HIV can develop high level resistance to some ARVs with a single mutation while other drugs 
require accumulation of multiple mutations. Each ARV drug has a different genetic barrier, i.e. 
threshold number of mutations required to cause clinically significant drug resistance (47). For 
example NRTI (3TC and FTC) and NNRTI (NVP and EFV) require one resistance mutation to 
acquire high level resistance therefore are considered as having low genetic barrier. The PIs 
and other NRTIs, such as AZT require accumulation of multiple drug resistance mutations to 
achieve high level phenotypic resistance and they are considered therefore as having high 
genetic barrier (30, 47).  However it is known that some mutations or combination of mutations 
can have greater effect than others (48), thus understanding the genetic barrier goes beyond the 
simple counting of  DRMs and involve the determination of the effect of  interaction of 
different mutations on HIV drug susceptibility (47).  
 
 
1.2.2.3. Drug potency, Adherence and resistance  
 
Adherence is defined as the extent to which the patients’ health related behaviour corresponds 
with the medical advice (49). Nearly perfect adherence to cART is the key factor to gain the 
intended health benefit. Suboptimal adherence or partial adherence results in insufficient 
bioavailability of the ARV to ensure complete suppression of the virus and therefore result in 
the development of HIV drug resistance and virological failure in patients on cART (50). 
Some drug resistant variants are thought to exist at very low levels before drug initiation from 
natural viral recombination (51, 52). If the patient receives an inadequate drug regimen or is 
poorly adherent to a correct regimen, the resistant HIV variants emerge, continue replication, 
accumulate resistance mutations and eventually cause treatment failure (53). 
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In the absence of ongoing drug selection pressure, reversion to wild-type HIV which has higher 
replication capacity occurs. However, various studies confirmed the persistence of drug-
resistant virus both in long-lived cellular reservoirs (54) and in blood plasma as minority 
species several months after treatment discontinuation (55, 56). Under drug selection pressure, 
this minority resistant virus can evolve later to cause significant pathogenicity (57). For this 
reason, the interruption of ineffective treatment as a strategy to permit the re-emergence of 
wild-type virus has been proven ineffective to address drug resistance issue (58). 
 
Adherence is an even bigger challenge in children, a dynamic population at different 
developmental stages, and dependant on care givers for medications. Poor availability of 
adequate drug formulation for younger children may result in inadequate drug levels and HIV 
drug resistance (59, 60). Furthermore, due to the developing metabolic pathways and rapid 
growth, paediatric patients are more likely to develop drug resistance from under dosing. 
Frequent dose adjustment are required to address this issue which is not always done correctly 
by all health care providers. Other factors include the premature release of responsibility to 
older children before they are developmentally ready to take over their own medication 
administration and psychological factors like denial, anger and depression in adolescents (19).  
In addition, programmatic factors such as insufficient or inadequately trained health care 
personnel and weak supply systems impair adherence and therefore must be addressed to attain 
optimal adherence (61). 
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1.2.3. HIV drug resistance test and clinical significance 
 
The immediate consequence of ARV resistance is reduction of treatment efficacy (27). The 
emergence of resistance to one ARV often leads to cross-resistance to other ARVs of the same 
class. This results from the similarities of the molecular structure within compounds of the 
same antiretroviral class and their interaction with similar target sites. 
 The reduction of therapeutic options which results from this cross-resistance lead to the 
prescription of more complex, expensive and often poorly tolerated regimens (27). This 
represents a major challenge especially in resource-limited settings where only few alternatives 
are available in the public sector and access to third-line agents may require significant time 
and resources.  
 
The drug resistance mutations can have multiple effects on ARVs.  Some drug resistance 
mutations confer increased susceptibility to ARVs (e.g: K65R increase susceptibility to AZT), 
can cause decreased viral replication abilities (e.g: M184V) (62) or are associated with a 
decreased incidence of other mutations like in case of M184V which is associated with low 
incidence of TAMs (63, 64).  Due to the this decrease in viral fitness, drugs like 3TC and FTC 
which select for the M184V mutation continue to provide some level of virological benefit 
even in case of high level resistance (65).  
 
1.2.4.  HIV drug resistance testing 
 
The testing of HIV drug resistance has become an integral part in HIV management in 
developed countries and is still not readily available in resource-limited countries (22, 66).  
Resistance assays can be grouped into two categories: Phenotypic and genotypic assays (67). 
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Phenotypic assays measure the in vitro ARV susceptibility of HIV strains in cell culture (68).  
Susceptibility to each ARV is reported as fold-changes in drug inhibiting concentrations as 
measured by comparing the mean inhibiting concentrations at which 50.0% replication of the 
testing HIV strain is suppressed (IC50)  relative to that of a reference HXB2 HIV strain. 
This method, although considered the gold standard, has several limitations; it is time 
consuming, costly, only be performed in a laboratory with high safety level (P3) and requires 
highly skilled staff. It is therefore,  not readily available in many (69). 
 
Genotypic assays determine the presence of mutations that are known to confer decreased drug 
susceptibility. The viral RNA is extracted from plasma and reverse transcribed.  The gene of 
interest, mainly the pol gene, is amplified and sequenced. The sequence is compared to the 
HXB2 sequence and differences are identified.  These differences are analyzed for their level 
of resistance. It only uses the resistance mutations which are already known but the results 
have been shown to be comparable to those generated by the phenotypic resistance test.  
Genotypic assays are faster, require less skill, are superior at detecting evolving resistance and 
are more affordable. For this reason the genotypic test is the commonly used test in clinical 
settings (69). 
 
Although the assay technology is improving,  both types of HIV drug resistance tests still face 
some challenges for detection of clinically significant minority species particularly in patients 
who were previously heavily treated and who have changed therapy (52, 69). 
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1.2.5. Interpretation of genotypic drug resistance  
 
Interpreting results of HIV-1 genotypic resistance tests is one of the most difficult tasks facing 
HIV clinicians. There are many different HIV-1 drug resistance mutations which may occur in 
complex patterns and may interact to cause varying levels of HIV-1 drug resistance to ARVs 
from each of the ARV classes.  
The presence of some mutations induce decreases in drug susceptibility and are referred to as 
“primary drug resistance mutation” while other mutations impact the drug susceptibility by 
enhancing the viral fitness of the virus harboring a primary mutation. These are termed 
“secondary drug resistance mutations” and they do not cause a decreases in drug susceptibility 
by themselves. Multiple DRMs may occur in a single sample and their interaction may result in 
an antagonistic or synergistic effect on drug susceptibility (48, 69).  
Given the complexity of these mutations, an interpretation system is necessary to help the 
clinicians. For this reason, several algorithms for the interpretation of HIV-1 genotypic drug 
resistance information have been designed (48).   
 
Most clinicians ordering HIV drug resistance tests use the publicly available web-based 
academic interpretation systems. There are more than ten academic systems for genotypic 
interpretation but only three of them are commonly used by clinicians: the Agence Nationale 
de Recherche sur le SIDA (ANRS) available on www.hivfrenchresistance.org, the Rega 
institute system from the Catholic University of Leuven available on 
https://rega.kuleuven.be/cev/regadb and the HIV drug resistance data base (HIV db) system 
from Stanford University available on http://hivdb.stanford.edu  (70). 
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All these interpretation systems are designed for clinical use and interpret HIV resistance using 
rules-based algorithms where each rule is conditioned upon the presence of certain mutations 
and assigns a level of inferred resistance to certain drugs. The rules used in these algorithms are 
frequently updated from HIV drug resistance literature and clinical data (70).  
 
The ANRS and Rega Institute systems are rules-based systems that report three levels of 
resistance: susceptible, intermediate, and resistant.  Both systems contain interpretations for all 
available antiretroviral drugs. They are frequently updated and widely accessible (70).  
 
The HIVdb system, also using a rules-based algorithm, is the most widely used and freely 
available online allowing clinicians and laboratories to interpret the HIV-1 resistance mutation 
test. The HIVdb internet interface (http://hivdb.stanford.edu/DR/webservices) accepts either 
nucleic acid sequences or lists of mutations. The sequence analysis form allows users to paste 
one or more HIV-1 protease, RT and/or integrase sequences into a text box or to upload a text 
file containing the same. The mutation list form allows users to type in lists of RT, protease, 
and/or integrase mutations or to select ARV resistance mutations from a drop-down menu (71). 
 
After uploading the sequence or the list of mutations, the output consists of: 
 A list of penalty scores for each resistance mutation in a submitted sequence,  
 Estimates of decreased susceptibility per ARVs class, and 
 The comments about each resistance mutation in the submitted sequence. 
The level of resistance are then determined based on the database algorithms. The HIVdb has 
5 levels of resistances: susceptible, potential low level resistance, low level resistance, 
intermediate resistance and high level resistance (71).  
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1.2.6. Benefits of HIV genotypic susceptibility testing  
 
It was demonstrated that the use of genotypic susceptibility testing in patients failing therapy 
leads to better viral suppression and improved survival compared to standard of care (72-74). 
In developed countries, HIV drug resistance testing has become an important clinical tool in 
the management of patients failing cART (66). In South Africa, drug resistance testing is not 
widely available in public settings. Other parameters such as viral load and CD4 cell count are 
monitored instead, to inform clinicians about patient compliance and treatment response. 
One major consequence is that children failing first-line regimen may be kept on the failing 
regimen or switched blindly onto more costly regimens with high side effect profiles with no 
real evidence of resistance or enough knowledge as to what the optimal new regimen should 
consist of. This decreases the likelihood of favorable treatment response in paediatric patients 
and could potentially compromise patient care (74).  
 
 
1.3. Study rationale  
 
To date, although more than 90.0% of patients with HIV-1 infection worldwide have non-
subtype B variants of HIV-1,  there is limited knowledge of drug resistance mutations in non-B 
subtypes of HIV-1 and their clinical relevance (30).  
Drug resistance mutation data is scarcer in children especially in resource-limited settings (29). 
To my knowledge few studies have been performed to explore HIV drug resistance patterns 
and consequences for future treatment regimens in the paediatric population in South Africa.  
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This study analyzed genotypic HIV drug resistance data from tests performed on selected 
patients at Empilweni Clinic, a paediatric HIV clinic in Johannesburg, with the aim of 
describing the HIV drug resistance profiles of patients who have had an HIV genotypic assay. 
Findings from this study will contribute to the availability of the HIV drug resistance data in 
resource-limited settings and will provide us with more insight on the HIV drug resistance 
patterns in paediatric patients. 
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CHAPTER 2.  OBJECTIVES OF THE STUDY 
2.1. Aim of the study  
 
To describe HIV-1 drug resistance patterns and the profile of patients who had genotypic HIV 
drug resistance tests at Empilweni Clinic between 1st January 2004 and 28th February 2012. 
 
 
2.2. Specific objectives  
 
1) To describe the profile of the patients who underwent a genotypic HIV drug resistance 
testing between 1st January 2004 and 28th February 2012. 
2) To describe HIV drug resistance patterns obtained, including the: 
a. Success rate of genotypic HIV drug resistance amplification; 
b. Frequency of important HIV polymorphisms in the protease gene; 
c. Frequency of important HIV drug resistance mutations [Appendix A]. 
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CHAPTER 3.   MATERIALS AND METHODS 
3.1. Study design  
 
A descriptive cross-sectional retrospective study was conducted on HIV-positive children on 
cART followed up at Empilweni Clinic who underwent HIV genotypic drug resistance testing 
between January 1st, 2004 and February 28th, 2013. The study included all children who 
underwent HIV drug resistance testing and whose medical files and results were accessible at 
the clinic. Demographic profiles (age, gender, and referral status), HIV subtype, the virological 
mutations and the genotypic drug resistances were assessed. 
 
3.2. Study setting 
 
This study was conducted at Empilweni Clinic, a large public paediatric HIV clinic operating at 
the Rahima Moosa Mother and Child Hospital (RMMCH) in Johannesburg, South Africa. It 
has been functional since 1995 and has grown rapidly since the Comprehensive HIV and AIDS 
Care, Management and Treatment for South Africa began in April 2004 (8).  The clinic acts as 
a referral centre for the public clinics from north western Johannesburg and occasionally 
private clinics from Johannesburg.  The patients are treated according to the national paediatric 
cART guidelines (75).  
During our study period the patients were treated according to national guideline. The 
following table summarizes the drug regimen used during our study period.  
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Table 2: Drug regimen used during our study period (76) 
 
Regimen  0 months up to 3 years Over 3years and >10 kg  
First-line Stavudine /Lamivudine 
Lopinivir/ritonavir 
Stavudine /Lamivudine 
Efavirenz 
Second-line Zidovudine / Didanosine 
Nevirapine/ Efavirenz* 
Zidovudine/Didanosine 
Lopinivir/ritonavir 
* Efavirenz if the child is over 3 years and Nevirapine if less than 3 years 
 
As in many other public institutions, HIV drug resistance testing is not readily available. At 
Empilweni Clinic, the collaboration with external institutions (Department of Molecular 
Medicine and Haematology, University of the Witwatersrand and the National Health 
Laboratory Services) has made this test available but only for selected cases.  The cases for 
genotypic HIV drug resistance testing were discussed in the clinical meetings at Empilweni  
Clinic and results were considered and reviewed on a dedicated clinic day.  
 
HIV drug resistance testing was done following case discussion and at the clinicians’ discretion 
in patients with virological failure whose viral load was above 1000 copies/ml for more than 
two visits done six months apart, whose adherence was judged to be adequate and where the 
child’s treatment history caused concern as to whether standard second line therapy would be 
adequate. Thus not all patients failing first or second-line therapy have HIV drug resistance 
tested systematically. 
 
The clinic has a database where all patient information is captured and updated on a daily basis. 
The patient’s files are kept in the clinic and access to both electronic and paper records is 
controlled by a dedicated gate keeper.  
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3.3. Study population 
 
Due to low frequency of genotypic HIV drug resistance testing in our setting, a convenience 
sampling method was used. All patients who underwent genotypic HIV drug resistance testing 
at the clinic during the study period were considered. Patients were excluded if their medical 
information was missing on the database or if their medical files could not be traced to retrieve 
missing information. 
 
3.4. Ethics and institutional approval 
 
This study was reviewed and approved by the scientific research committee [Appendix B]. 
Ethical clearance to use patient records was obtained through the human research ethic 
committee of the University of the Witwatersrand with Ethics clearance number M130222 
[Appendix C].  Hospital approval was obtained from the chief executive officer of RMMCH 
[Appendix D].  
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3.5. Data collection   
 
The genotypic HIV drug resistance test was performed by the NHLS (national Health 
Laboratory Services). After the viral RNA was extracted from plasma and reverse transcribed, 
the gene of interest was amplified and sequenced. The sequence was then compared to HXB2 
and differences from the sequence were identified. The level of resistance was determined 
using the HIVdb algorithm freely available on http://sierra2.stanford.edu/sierra/servlet/JSierra. 
The mutations were displayed on the results sheet together with the genotypic susceptibility of 
the common ARVs used in South Africa. We considered as relevant the drug resistance 
mutations from the IAS-USA March 2013 update [Appendix A]. 
 
After obtaining the result sheets of the HIV drug resistance test, a research ID was allocated 
and relevant information including date of sample collection, HIV subtype, resistance 
mutations and polymorphism were captured on a Microsoft Excel database. For each patient 
whose genotypic HIV drug resistance results were available at the clinic, relevant medical files 
were extracted from the clinic archive. 
 
They were used to review and update the clinic database for those specific patients. Further 
demographic and medical information was extracted from the clinic database after its review. 
Extracted information included gender, age, history of tuberculosis, PMTCT, treatment 
initiation CD4 cell count and viral load, regimen, date of initiation of cART and the date of 
HIV drug resistance genotype testing as well as whether the patient was transferred in on ART 
from another facility or not.  
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3.6. Statistical analysis 
 
Data was analyzed descriptively using STATA (version 11). For categorical variables such as 
gender, race, clinical information and HIV drug resistance test results, frequencies and 
percentages were computed whereas, for continuous variables such as age, means and standard 
deviations were calculated for normally distributed data. For non-normally distributed data, 
medians and interquartile ranges (IQR) were computed. Resistance mutations were presented 
in bar graphs, and demographic and clinical characteristics were presented in frequency tables.  
The χ2 (Chi-square) test was used for computation of different proportions between groups.  
The statistical significance was confirmed with p<0.05.  
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CHAPTER 4.  RESULTS  
4.1. Source of the study population  
 
The study overview is depicted in Figure 1. From the 1st January 2004 to 28th February 2012, 
68 samples were sent for genotypic HIV drug resistance testing from the Empilweni Clinic. 
Five of these patients were excluded from our study as they had no information available on 
the clinic database and we could not trace the medical files.  
 
Among the 63 patients whose samples were sent for genotypic HIV drug resistance testing and 
whose medical files were available for review, nine patients had a genotypic HIV drug 
resistance test repeated twice and one patient had the test repeated three times. The last time 
point on record for each patient was considered for genotypic HIV drug resistance analysis in 
these ten subjects.  
 
Overall 52 patient samples were included in the analysis with an amplification rate of 84.6% 
(n=44).  All the patients whose samples were successfully amplified were infected with HIV 
subtype C. The rest of the samples (16.4%, n=8) failed to amplify due to low viral load.  
The following figure depicts an overview of the enrolment process in our study. 
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Figure 1: Enrolment algorithm of the paediatric HIV drug resistance study at Empilweni              
Clinic 
 
 
4.2. Patient demographic characteristics  
 
The main demographic characteristics of our study population are summarized in Table 1. Of 
the 52 children with genotypic HIV drug resistance results, the majority were males (55.8%; 
n=29). Most of the patients were initiated on cART at the clinic (N=39, 75%) as soon as 
possible after the first visit and 13 patients (25%) were referred to our centre already on cART. 
The median age at initial visit at our clinic was 28.5 months (IQR: 6-89.5). The mean age of 
initiation on cART was 25.5 months (IQR: 7-89.5) with 36.5% (n=15) initiating cART before 
one year of age and half of the patients (50.0%, n=26) having started cART before the age of 
two. At the time of genotypic HIV drug resistance testing, the median age was 59.5 months 
(IQR: 28-138.5) and the median duration on cART test was 26.5 months (IQR: 16-39.5). 
68 patient samples sent for HIV genotyping 
52 patient samples considered for our study
44 patient samples (85%) amplified 
successfully
All of these were HIV subtype C
8 patient samples (15%) failed to amplify
5 patient samples not considered as no 
further clinical details were  available 
11 patient samples exluded to avoid 
duplication  of the results
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Table 3: Demographic characteristics of patients enrolled in our study 
 
DEMOGRAPHIC CHARACTERISTICS 
Characteristic Designation  Number Percentage (%) 
Sex Male 29 55.8 
Female 23 44.2 
 
 
Age 
(Months) 
 
at initial visit  Median: 28.5 (IQR 6-89.5) 
 
at initiation of cART 
(median & IQR): 25.5 (IQR: 7-89.5) 
 
< 12 17 32.7 
13-24 9 17.3 
25-60 6 11.5 
61-120 15 28.9 
> 120 5 9.6 
at genotypic HIV drug resistance 
test 
Median:  59.5 ( IQR 11-205) 
Transferred in on cART Yes  13 25.0 
No  39 75.0 
 
 
4.2. Pre-treatment clinical characteristics 
 
The main pre-treatment clinical characteristics are summarized in Table 2. Among 52 patients 
enrolled in this study, more than a third (N=19, 38%) presented early to the clinic at WHO 
stage I. The median VL at cART initiation was 5.2 logs (IQR: 3.1-6.6) with a median CD4 cell 
count of 447 (IQR: 214-796). The majority of the study population had no known history of 
PMTCT (N=28, 53%). Thirty patients (56.6%) had been treated for tuberculosis before HIV 
drug resistance testing was performed. The initial regimen which was commonly used in our 
population study consisted mainly of a PI-based regimen (53.9%) with LPV/r (Kaletra®) being 
the main PI used.  
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Full dose Ritonavir was used in only two patients (3.8%) as initial regimen, one of them was 
switched to Kaletra® after 6 months and the other patient switched after one year on Ritonavir. 
The switch was done more than a year before the resistance test.  
All the patients who were on NNRTI-based regimens (46.1%) received EFV, except one 
patient who received NVP. D4T/3TC was the main NNRTI combination used in 73.5% (n=39) 
of the cases. Before the genotypic HIV drug resistance test many patients on NNRTI were 
already switched to PI-based therapy (40.4%; n=21) and 20 patients (38.5%) had only been on 
PI-based regimen; thus 78.9% of patients had PI exposure before the test. 
  
      Table 4: Clinical characteristics of patients enrolled in our study 
CLINICAL CHARACTERISTICS 
Characteristic Count Percentage (%) 
WHO stage at initial visit 
I 19 38.0 
II 9 18.0 
III 14 28.0 
IV 8 16.0 
Not available 2 NA 
CD4  cell count at initial visit 
Median & range (cells/µl):  
447 (214-796) 
 
           < 100 7 13.7 
100-500 20 39.2 
501-1000 13 25.5 
> 1000 11 21.6 
Not available 1 NA 
Viral load in log10 copies/ml 
at initial visit 
Median: 5.2 (IQR 3.1-6.6) 
3-5 21 42.0 
>5 29 58.0 
Not available 2 NA 
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Table 3: Clinical characteristics of patients enrolled in our study (continued) 
Characteristic Count Percentage (%) 
Viral load before resistance test 
(in log10 copies/ml)  
Median: 4.26 (IQR 3.6-4.5)  
< 3 6 14.0 
3-5 28 65.0 
   >5 9 21.0 
PMTCT 
Yes 17 37.8 
No 28 62.2 
Not available 7 NA 
History of TB 
Yes 30 57.7 
No 22 42.3 
Drug exposure before HIV drug 
resistance testing 
NNRTI backbone 11 21.1 
PI backbone 20 38.5 
Regimen switch 21 40.4 
Duration on cART (months) 
before the HIV drug resistance 
test in months 
Median: 26.5 
 (IQR 16-39.5) 
< 12 7 13.4 
12-24 16 30.8 
> 24 29 55.8 
 
 
 
 
  
 
27 
4.3. Genotyping results  
4.3.1. HIV subtype and overall resistance mutations  
 
All the patients who had a successful amplification of the PR and RT coding regions (n=44) 
were infected with HIV-1 subtype C. At least one resistance mutation was identified in 90.9% 
(n=40) of the cases. Thirty five patients (79.5%) had at least one mutation isolated in the RT 
gene and 13 patients (29.5%) had two or more resistance mutations in the PR gene. Four 
patients (9.0%) had no known drug resistance mutations detected.   
 
4.3.2. Nucleoside reverse transcriptase inhibitors (NRTI) mutations 
 
The frequencies of the NRTI mutations are shown in Figure 2. The most commonly observed 
NRTI mutation was M184V (65.9%; n=29), it was the only mutation identified in 36.3% of the 
cases (n=16). This was followed by thymidine analogue mutations (TAMs) (25.0%, n=11) 
which resulted in a decreased susceptibility to AZT and d4T.  Six patients (13.6%) had M184V 
associated with at least one TAM. 
 
 Of the 11 patients who had TAMs, 7 of them (77.8%) had TAM2 (D67N/K70R/T215F) and 
two patients (22.2%) had TAM1 mutations (M41L/L210W/T215F) identified. Two patients 
(4.5%) had two TAM1 mutations (K70R/T215F) accumulated and one patient had three TAM1 
accumulated (M41L/L210W/T215Y). We did not identify both TAM pathways in the same 
viraemic sample. TAM2 mutations, the most commonly selected pathway, were identified as 
follows: D67N (8.9%, n=4), K70R (8.9%, n=4), and T215F (4.5%, n=2).  
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The K65R and L74V mutations, which result in decreased susceptibility to TDF/ddI were 
identified in only 2.2% (n=1) and 4.5% (n=2) cases, respectively. The Q151M complex and 
associated mutations and the T69N insertion were identified in only 2.2% (n=1) and 8.9% 
(n=4) patients, respectively. 
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Figure 2: Frequency of drug resistance mutations associated with resistance to Nucleotide 
Reverse Transcriptase Inhibitor (NRTI); the most frequent mutation observed was 
M184V (65.9%, n=29). 
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4.3.3. Non-nucleoside reverse transcriptase inhibitors (NNRTI) mutations 
 
The identified NNRTI mutations are summarized in Figure 3. Among the patients failing 
NNRTI-based therapy (n=32), 14 patients (43.8%) had at least one NNRTI mutation identified. 
The mutations V106M and K103N were the most identified and were equally observed (n=7, 
21.9%). Both mutations were not observed in the same vireamic sample. Other NNRTI 
mutations identified were Y188H/L (15.6%), G190A/S/E (15.6%) and Y181C (6.3%). The 
minor NNRTI mutations identified were V179D/E (9.4%), K101P (6.3%), V108I (6.3%) and  
E138A (3.1%).  
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Figure 3: Frequency of drug resistance mutations associated with resistance to Non-
Nucleotide Reverse Transcriptase Inhibitor (NNRTI), the most frequent mutations 
observed were K103N (21.9%; n=7) and V106M (21.9%; n=7). 
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4.3.4. Mutations associated with resistance to Protease inhibitors 
 
Among the 41 patients who were exposed to PI based regimen, the PR gene mutations 
identified were V82A/F (29.3 %, n=12), T74S (24.4 %, n=10), I54V (22.0%, n=9), L76V 
(14.6%, n=6) and M46I (14.6%, n=6) as depicted in Figure 4. 
Twelve of these patients (29.3%) had two or more PR gene mutations identified.   
 
 
 
Figure 4: Frequency of Protease (PR) mutations in the patients failing Protease Inhibitor (PI) 
based regimen, the most commonly identified mutation was V82A/F (29.3%, n=12) 
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4.3.4. Protease gene polymorphisms  
 
All the PR polymorphisms observed in patients exposed to PI based regimen (n=41) are 
summarized in Figure 5. The most common PI polymorphisms identified in our population 
were H69K (87.8%, n=36), M36I (75.6%, n=31), L89I/M (73.2%, n=30), L63P (63.4%, n=26) 
and R41K (56.1%, n=23). 
 
 
Figure 5: Frequency of Protease (PR) polymorphisms in patients failing Protease Inhibitor 
(PI) based therapy.  
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4.4. Genotypic susceptibility 
 
Figure 6 shows the distribution of the patients according to the genotypic susceptibility.  Of the 
patients who had successful amplification, almost a third (72.7%, n=32) had genotypic 
resistance to at least one ARV used in South Africa. All of these had a genotypic resistance to 
at least one NRTI with 50.0% of them (n=16) experiencing resistance to only 3TC and FTC.  
Twenty seven percent (n= 12) of these patients were still susceptible to all ARVs.  
 
 
Figure 6: Distribution of the patients according to genotypic susceptibility  
 
Two patients (4.5%) had genotypic drug resistance to all NRTI available in South Africa with 
intermediate susceptibility to TDF as they did not have K65R mutation. One had Q151M 
complex together with T69N insertion and the other one had accumulated 3TAMs amongst 
other mutations. 
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Among the patients exposed to NNRTI, sixty three percent (n=20) were resistant to at least one 
NNRTI. In our cohort, exposure to ART as part of PMTCT was not associated with having 
NNRTI genotypic resistance (p=0.393).  
The majority of the patients exposed to PI backbone therapy before the genotypic HIV drug 
resistance test (n=41), were still sensitive to all the PI used in South Africa.  Twelve patients 
(29.3%) had two or more PR gene mutation which was associated with genotypic drug 
resistance to at least one of the PI available in South Africa (p<0.001).   
Among the patients who amplified successfully (n=44), 21 patients (47.7%) had a dual class 
resistance (NRTI and NNRTI) and 5 (11.4%) had genotypic resistance to ARVs from all the 
three classes (NRTI, NNRTI, and PI). 
In a univariate logistic regression model (table 4), no individual factor; including age, duration 
on cART before drug resistance test, history of TB treatment, viral load before the resistance 
test and PMTCT exposure, was associated with developing genotypic resistance to ARVs.  
Table 5: Univariate logistic regression analysis  
                      Independent             
                           variable   
Dependent 
variable                                  
                           Genotypic resistance to any ARV 
P value 
Age at initiation 0.85 
Duration on cART before 
HIV drug resistance test 
0.93 
PMTCT exposure 0.25 
Viral load at HIV drug 
resistance test 
0.90 
History of TB 
0.17 
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CHAPTER 5.  DISCUSSION 
Although the HIV transmission rate is declining in South Africa (77), it still poses a serious 
public health problem with children being the most vulnerable group (25). This study focused 
on the mutations and genotypic susceptibility of the children who underwent genotypic HIV 
drug resistance testing from a public hospital after virological failure. The drug resistance 
mutations in our cohort has a complex pattern with almost half (47.7%) of the patients 
harbouring dual class drug resistance and  11% of the patients with genotypic resistance to all 
three classes while over a quarter of the patients (27%) still sensitive to all ARVs.  
 
5.1. HIV clade and genotypic resistance profile 
 
All the patients who had their vireamic samples successfully amplified were infected with HIV 
subtype C. Ninety one percent (91%) had at least one resistance mutation isolated. These 
results are similar to previously published studies from South Africa (78-80).  The frequency of 
DRMs in our cohort is consistent with findings form a systematic review of resistance in 
children failing therapy from resource-limited settings which reported a pooled proportion of 
90% of children failing cART with any DRM (25)  
 
The majority of the patients (78%) were exposed to PI inhibitors before the genotypic HIV 
drug resistance test. As per current national paediatric ART protocol, the PI-based regimen was 
the commonly used initial cART in our population (53%) and a quarter of the patients (25%) 
had a regimen switch from NNRTI-based regimen to PI-based regimen.  
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We observed resistance mutations for all three major ARV drug classes used in South Africa. 
Almost two thirds of the patients (73%) had genotypic resistance to at least one ARV used in 
our settings, 47.7% had dual class resistance and 11% were resistant to drugs from three 
classes. TAMs were identified in 15.3% of the cases with 4.5% having two TAMs. This 
complexity of the mutation patterns in our population suggest a potential need for drug 
resistance test in paediatric population to determine appropriateness of regimen switch and to 
preserve first-line regimen where possible.  
 
Over a quarter (27%) of the patients with virological failure had no genotypic drug resistance 
to any drug used in South Africa. The median RNA load at initiation was 5.1 logs (IQR: 3.1-
6.6) and 4.2 logs (IQR: 3.6-4.5) at time of resistance testing. The most plausible reason for this 
treatment failure with no drug resistance identified is poor adherence even though the patients 
were reporting nearly perfect adherence. Previous studies have shown that self-report by 
paediatric patients overestimates adherence when compared to pharmacy records (81). This 
shows that clinicians may assess a patient as having good adherence and be suspicious of them 
having mutations but the results may show that this is not the case in up to a quarter of cases.  
Furthermore, this underscores the importance of adherence counselling and various adherence 
support measures and the role of drug resistance testing in paediatric patients failing treatment 
to avoid unnecessary switching and prolonging first-line regimen, thereby prolonging the 
duration of ART success in resource-limited settings.  Therefore, as the VL monitoring 
becomes increasingly available in resource-limited settings the adherence counselling and 
support should be the first focus before drug resistance testing. Adult studies from developing 
countries provided evidence that, in patients failing cART, targeted counselling can lead to 
viral re-suppression in some cases averting the need to switch therapy (82).   
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In our cohort, the genotypic drug resistance testing was selective and not every patient who 
required the test could get it. Only patients with relatively complex ARVs history had the test 
done. This could have contributed to the low percentage of patients with no genotypic drug 
resistance.  
 
5.2. NRTI mutation patterns  
 
The NRTI mutations were the most commonly observed DRMs in our series. The M184V 
conferring high level resistance to 3TC/FTC and TAMs conferring resistance to most NRTI 
were the most commonly identified in 64% and 15.6% of cases, respectively. Six patients 
(13.6%) had M184V with at least one TAM.  Due to a small sample size, the comparison of the 
prevalence of TAMs in groups with and without M184V could not be performed, but it has 
been previously reported that the presence of M184V decrease the incidence of TAMs (83).  
 
The most commonly identified TAM was D67N and K70R which was observed in 8.9% of 
cases. This suggest that in our series TAM2 pathway was the most favourably selected 
compared to TAM1 pathway which might be of some advantage since the TAM2 resistant 
virus is relatively less fit compared to TAM1 resistant virus (84, 85) 4.5% of our patients had 
accumulated two TAMs and only one patient had three TAMs.  
The TAM patterns in this study are similar to those previously published studies done in South 
Africa and Kenya where the patients had routine follow up and VL monitoring (79, 86). 
However, the prevalence of TAMs and M184V observed in our cohort is lower compared to 
other studies done in developing countries where the monitoring was less intense.  
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A recently published study from Uganda by Musiime et al., reported the M184V mutation in 
90.8%, TAMs in 43% and 10.9% of children failing first-line regimen had accumulated 3 or 
more TAMs. In the study, similarly to our findings, K65R was identified in only 2.8% (87).  
 
This high prevalence of M184V mutation in both studies can be explained by the common use 
of 3TC or FTC in the first-line regimen. The high prevalence of TAMs in the Ugandan study 
might be explained by a prolonged duration on failing cART. This is consistent with Gupta et 
al.’s findings in his Zambian cohort (88) where a more rapid accumulation of TAM in children 
compared to the rate previously reported in adult studies was reported (89). While the average 
duration on cART in our study was only 26.5 months, it was 70.8 months in the Ugandan study 
(87).  
 
Our results are different from those published by Almeida et al. from Brazil where the TAM 
T215Y/F was the most commonly identified mutations (69.6%) with M184V identified in only 
56.5% of the cases. This difference might be explained by different drug regimens and the 
duration on cART. In their study the patients were mainly exposed to AZT/ddI containing 
regimen and the median time of exposure to cART was 60 months while our patients were 
mainly on d4T containing regimen with a median time of exposure of 26.5 months (90). 
Previous studies have suggested that AZT-containing regimen is more likely to select for 
TAMs compared to d4T containing regimen (25, 87).  
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Another possible explanation is the difference in pathways of developing DRMs among 
different HIV subtypes. In our cohort all the patients had HIV subtype C while in the study by 
Almeida et al. the patients were mainly infected by HIV subtype B (78.3%) and only 4.3% 
were infected with HIV-1 subtype C.  In a published review article, Wainberg et al. suggested 
that HIV-1 subtype B have  a higher propensity to acquire TAMs compared to HIV-1 subtype 
C, while subtype C have a differential selection of K65R instead (41).  
The K65R resulting in decreased susceptibility to TDF and ddI was observed in only one 
patient (2.3%). Our rate is similar to the rates previously reported from studies done in similar 
settings. Van Zyl et al. who reported the K65R prevalence of 2.8% in South African patients 
failing d4T containing regimen and Wamalwa et al., in a Kenyan paediatric cohort, observed a 
rate of 2.9% (86, 91). However, our rate is lower than the rate reported by Puthanakit et al. in a 
cohort of Thai children failing NNRTI-based therapy where the K65R mutation was identified 
in 5% of the cases (92).  The relatively high rate reported in the Thai study might have been a 
result of rare virological monitoring which was only done once treatment failure was suspected 
based on clinical and immunological criteria. A systematic review from adult studies showed 
that routine virological monitoring allows for on time identification of treatment failure and 
intervention thus limiting the occurrence of DRMs (92, 93).  
 
The Q151M complex conferring multi-NRTI resistance except TDF, was defined as Q151M 
alone or in combination with one or more of the following mutations: A62V, V75I, F77L, and 
F116Y.  It was identified in one patient (2.3%) and was not associated with K65R which 
results in multi-NRTI resistance including TDF.  This patients was on failing regimen 
(d4T/3TC/EFV) since July 2005 and was never virally suppressed until switched to second-line 
PI based regimen in January 2008 after the genotyping resistance test.  
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These findings are consistent with the previously published adult study by Zaccarelli et al., 
suggesting that the detection of Q151M mutation increases with the duration on failing NRTI 
therapy (94). Our findings are also similar to a recently published study from South Africa by 
Van Zyl et al. who reported a Q151M prevalence of 1.9% among paediatric patients failing 
first-line regimen (91). 
 
5.4. NNRTI mutation patterns  
 
Almost half of the patients (43.8%, n=14) exposed to NNRTI were resistant to at least one 
NNRTI. The K103N and V106M mutation were the most common NNRTI mutations, 
identified in 29.1% of the patients exposed to NNRTI-based regimen before resistance test. 
These mutations confer high level resistance to most commonly used NNRTIs but they have no 
effect on the susceptibility ETR which is a recently introduced NNRTI. 
The K101E and Y181C mutations were identified in only 6.3% of the patients exposed to 
NNRTI-based regimens. This rate is comparable to the rate reported in recently published 
study from KwaZulu-Natal Province (KZN) (79).  
 
The patterns of the NNRTI mutations in our cohort suggest that ETR can be still an option after 
failing conventional NNRTI-based regimens in this age group. 
 
The positive PMTCT history was not statistically associated with any NNRTI mutation or with 
genotypic resistance to NNRTI, consistent with an observation from a recently published study 
from South Africa noting that PMTCT history is not reliable in ruling out pre-treatment HIV 
drug resistance (95).  
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5.5. Protease mutation and polymorphism patterns  
 
In the study population the PI based therapy was the main regimen used with 78% of the 
patients exposed to this regimen before resistance test. The median duration on treatment was 
26.5 months (IQR 16-39.5). Despite this relatively long exposure, only 29% of these patients 
developed genotypic resistance to at least one PI commonly used in South Africa. This might 
be explained by the high genetic barrier of PI but also raise the possibility of poor and 
differential adherence to Kaletra® as it can be poorly tolerated especially in young children 
(96).  
The V82A was the most commonly observed PR mutations and was observed in 29.3% of the 
patients exposed to PI. The double substitution V82A/I84V is known to confer resistance to all 
PR inhibitors was not identified in our study.  In our study, the PR mutations rate was much 
higher than the rate recently published from KZN, where Pillay et al. identified V82A mutation 
as the only mutations in 6.3% of their rural area cohort (79).  This difference might be 
explained by the different exposure to PI drugs. In our cohort 93.1% (n=41) of the patients had 
been exposed to a PI based regimen by the time of drug resistance testing while only 15.8% 
(n=16) had been on PI regimen in Pillay’s cohort (79) . Two patients had received full dose 
Ritonavir but they were switched to Kaletra® more than a year before the genotypic resistance 
test. 
This might have contributed to the increase of the rate of PR resistance mutations in our cohort. 
In Pillay’s cohort, 17.8% of the cases were on PI based therapy with various adherence patterns 
by the time of genotyping (79). The relative high prevalence of PI resistance in our study is a 
cause of concern since PI are considered as the pillar of the paediatric HIV care.  
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The PR polymorphisms H69K, M36I and L89I/M were the most common and were identified 
in 87.8%, 75.6% and 73.2% of the patients exposed to PI based regimen, respectively. This 
high level of polymorphism is a cause of concern in our settings. Although they do not seem to 
cause drug resistance on their own but they may have compensatory roles such as enhancing 
viral replication or aid the virus in developing active site drug resistance mutations (97, 98).  
Velazquez-Campoy et al. proved that high level of polymorphisms in HIV-1 subtype C 
contribute on the reduction of the effectiveness of PR inhibitors binding onto substrate (99) and 
Clemente et al. suggested that HIV-1 subtype C harbouring M36I as a natural polymorphism 
could aid the virus to develop active site mutation while maintaining catalytic activity(100).  
 
5.6. Limitations of the study 
5.6.1. Sampling  
 
In this study, a convenience sampling method was used. However, during the study period only 
a few resistance tests were performed due to the low incidence of the treatment failure and 
limited availability of the genotyping drug resistance test in the clinic.  Therefore, due to the 
small size the mutation pattern observed might represent the reality of our clinic but not easy to 
generalize it to the rest of the population.  
We could not identify any factor associated with developing resistance to ARVs in our study 
probably because of a small number of the patients who underwent genotyping in our study 
period.   
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5.6.2. Selection bias 
 
The HIV drug resistance testing was performed following individual case discussion and at the 
clinicians’ discretion in patients with virological failure whose HIV- RNA was above 1000 
copies/ml for more than two visits done six months apart.  
Thus not all patients failing therapy received systematic testing of HIV drug resistance; this 
may have caused selection of cases with complicated ARVs history and probably more 
complex mutation profile. 
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CHAPTER 6.  CONCLUSIO N AND RECOMMENDATIONS 
The study findings suggest the existence of complex drug resistance mutations pattern in 
paediatric patients failing therapy in resource-limited settings.  
Given this complex resistance mutation patterns in paediatric patients we recommend regular 
VL monitoring at least 6 monthly and genotypic HIV drug resistance testing in case of any 
virological failure.  
The viral load monitoring will facilitate rapid identification of virological failure, and the 
genotypic HIV drug resistance test will prevent unnecessary switches, thereby preserve first-
line regimens where appropriate and avoiding prolonged duration on a failing regimen where 
HIV drug resistance is identified. This will ensure the continued cART success in the paediatric 
patients.   
Yet the complex patterns of resistance mutations in the paediatric population and the absence 
of resistance in some patients failing therapy as demonstrated in our study underscores the 
importance of adherence counselling and adherence support measures as a key factor for a 
durable ART success. 
The frequency of drug resistance mutations are closely related to the drug regimen and duration 
of exposure in poorly compliant children.  
Additional large studies on drug resistance mutation in paediatric population and their impact 
on clinical outcomes are warranted to further enlighten this clinical puzzle.  
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